NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.367) was uploaded to the NHS England Website on Friday 27, June 2025.
The following changes have been introduced:
Zanubrutinib (ZAN6)
For the treatment of patients with relapsed/refractory mantle cell lymphoma in patients who have received only 1 prior line of systemic therapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Blinatumomab (BLI6)
The treatment of POST PUBESCENT CHILDREN in first morphological complete remission and without minimal residual disease after 1st line intensive induction and any indicated intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia where the following criteria have been met
Recommended for routine commissioning, straight into section B of list
Blinatumomab (BLI5) ## Blinatumomab (BLI5)
The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met: The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met:
Moved into routine commissioning - section B of list Treatment criteria (#9 and 11) updated
Lisocabtagene maraleucel (LIS01a) ## Lisocabtagene maraleucel (LIS01a)
Lisocabtagene maraleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma or primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B either in patients who relapsed within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS1b) can only be completed as a continuation of this first part of the form (LIS1a) and must completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel Lisocabtagene maraleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma or primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B either in patients who relapsed within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem transplantation where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS1b) can only be completed as a continuation of this first part of the form (LIS1a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel
Moved into routine commissioning - section B of list Moved into routine commissioning - section B of list
Lisocabtagene maraleucel (LIS01a) ## Lisocabtagene maraleucel (LIS01a)
Lisocabtagene maraleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma or primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B either in patients who relapsed within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem cell transplantation where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS1b) can only be completed as a continuation of this first part of the form (LIS1a) and must completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel Lisocabtagene maraleucel for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high grade B-cell lymphoma or primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B either in patients who relapsed within 12 months of completion of 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem transplantation or who are refractory to 1st line chemoimmunotherapy AND who would otherwise be intended for potential stem transplantation where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS1b) can only be completed as a continuation of this first part of the form (LIS1a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel
Moved into routine commissioning - section B of list Moved into routine commissioning - section B of list
Blinatumomab (BLI4)
The treatment of patients in first complete haematological remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria have been met:
Treatment criteria (#6, 7, 8, 11 and 13) updated
Blinatumomab (BLI5) ## Blinatumomab (BLI5)
The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met: The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met:
Moved into routine commissioning - section B of list Treatment criteria (#9 and 11) updated
NA (BRE3)
NA
Treatment criteria (#5 and 9) updated
NA (BRE5)
NA
Treatment criteria (#6 and 8) updated
Brentuximab (BRE7)
Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma ADULT patients:
Treatment criterion (#9) updated
Darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) (DARO2)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer where the following criteria have been met
Treatment criterion (#3) updated
Ibrutinib (IBR5)
For the treatment of relapsed/ refractory mantle cell lymphoma in patients who have either only received 1 prior line of systemic therapy or been treated with prior lines if 2nd line therapy was initiated before NICE’s recommendation in January 2018 where all the following criteria are met:
Treatment criteria (#1, 3, 4, 5, 7, 9, 10 and 11) updated
Osimertinib in combination with pemetrexed and platinum- based chemotherapy (OSI4)
Osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first line treatment of adult patients with recurrent or locally advanced or metastatic non-small cell lung cancer exhibiting epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations where the following criteria have been met
Treatment criteria (#4, 6 and 7) updated
Trastuzumab deruxtecan (TRAD1)
For treating over-expressed HER2 positive unresectable locally advanced or metastatic breast cancer in patients who have received 2 or more anti-HER2 therapies and who have received trastuzumab emtansine in the advanced/metastatic disease setting where the following criteria have been met
Treatment criterion (#12) updated
Trastuzumab deruxtecan (TRAD2)
For treating over-expressed HER2 positive unresectable locally advanced or metastatic breast cancer in patients who have received 1 or more anti-HER2 therapies and who are treatment-naïve for trastuzumab emtansine in the advanced/metastatic disease setting where the following criteria have been met
Treatment criterion (#13) updated
Zanubrutinib (ZAN5)
Zanubrutinib monotherapy for the treatment of patients with marginal zone lymphoma treated with at least 1 prior anti-CD20-based therapy where the following criteria have been met
Treatment criterion (#11) updated
Atezolizumab (ATE10)
Atezolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease is all of the following: has PD-L1 expression on ≥50% of tumour cells, is not EGFR mutant or ALK- positive and has not progressed on recently completed adjuvant platinum-based chemotherapy where the following criteria have been met
Date moving into routine commissioning updated